AT RUBICON RESEARCH,
PARTNERING IS A PRIORITY.

At Rubicon Research, we are driven by innovation and leadership, with the vision to become one of the top 10 generic companies in the US in the next five years. Our strong presence in western markets is due to our deep expertise in developing generic and complex products, and we currently have over 90 products in the development pipeline.

To achieve our vision, we pursue both organic and inorganic growth opportunities, and are in search of partners who share our values and commitment to deliver better healthcare. We are interested in expanding our footprint globally, starting with the US market through our subsidiary Advagen Pharma Ltd.

Our growth efforts are directed towards collaborations where we can leverage our expertise in formulation development and patented drug delivery technologies with innovators that bring the actual drug candidate, so as to create value-added specialty products. Apart from product-based co-development partnerships, we also focus on equity-based partnerships (product and corporate level).

Our focus on research and development at scale has resulted in us having a portfolio of 59 active ANDAs as of March 31, 2024, of which 14 approvals were received in Fiscal 2024. As on March 31, 2024, we have 47 Commercialized Products that are being marketed and sold in the US, including seven specialty products.As on March 31, 2024, we sell two third-party products where we neither own the ANDA nor manufacture the products, namely Venlafaxine extended - release capsules and Mycophenolate Mofetil tablets and capsules. In selecting such products, we consider our customers’ requirements, our assessment of the competitive advantage created by the manufacturer, the product’s fit with our basket of products and our sales and marketing channels. These products contributed 1.43% of our revenue from operations in Fiscal 2024.

We believe that our product development capabilities backed by experience in navigating regulatory pathways, large-scale commercial manufacturing and marketing capabilities for branded and non-branded products uniquely position us as a co-development and commercialization partner for early-stage and pre-clinical stage companies. In instances where we co-develop products,

We collaborate with third parties and have arrangements in place for sharing the development costs and agree to pay certain amounts upon completion of milestones specified in the agreement and to a profit share with the co-developer. We either own the intellectual property associated with these products or secure licenses for exclusive use of the intellectual property and undertake the process of applying for and obtaining the regulatory approval. We currently have two products filed with the USFDA pursuant to such arrangements.

We intend to continue to seek additional opportunities that enable us to leverage our research and development to bring innovative products to market with commercial models that we believe can deliver substantial growth and profitability. We intend to opportunistically pursue opportunities to expand our manufacturing capabilities with acquisitions of facilities in India with existing regulatory approvals and capabilities that are complementary to our 225 product portfolio and products under development as approved by our Board pursuant to its resolution dated July 29, 2024.

With the acquisition of Impopharma Canada, Rubicon Research has also acquired expertise to evaluate and develop drug device combination products, and is also keen to explore business avenues in this space.

Over the years Rubicon Research has built and expanded on its strong strategic partnerships, primarily in development, manufacturing, and regulatory support of pharmaceutical products. We actively seek to establish and strengthen long-term business relationships through avenues like co-development, acquisitions, or fees for service. We understand the importance of building these relationships to address unmet healthcare needs around the world.

We would love to start a conversation.